PL2137192T3 - Pochodne galantaminy jako proleki do leczenia chorób mózgu u ludzi - Google Patents

Pochodne galantaminy jako proleki do leczenia chorób mózgu u ludzi

Info

Publication number
PL2137192T3
PL2137192T3 PL08735211T PL08735211T PL2137192T3 PL 2137192 T3 PL2137192 T3 PL 2137192T3 PL 08735211 T PL08735211 T PL 08735211T PL 08735211 T PL08735211 T PL 08735211T PL 2137192 T3 PL2137192 T3 PL 2137192T3
Authority
PL
Poland
Prior art keywords
galantamine
pro
drugs
derivatives
treatment
Prior art date
Application number
PL08735211T
Other languages
English (en)
Inventor
Alfred Maelicke
Original Assignee
Neurodyn Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40019199&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2137192(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Neurodyn Life Sciences Inc filed Critical Neurodyn Life Sciences Inc
Publication of PL2137192T3 publication Critical patent/PL2137192T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL08735211T 2008-04-14 2008-04-14 Pochodne galantaminy jako proleki do leczenia chorób mózgu u ludzi PL2137192T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2008/002929 WO2009127218A1 (en) 2008-04-14 2008-04-14 Derivatives of galantamine as pro-drugs for the treatment of human brain diseases
EP08735211.8A EP2137192B8 (en) 2008-04-14 2008-04-14 Derivatives of galantamine as pro-drugs for the treatment of human brain diseases

Publications (1)

Publication Number Publication Date
PL2137192T3 true PL2137192T3 (pl) 2014-07-31

Family

ID=40019199

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08735211T PL2137192T3 (pl) 2008-04-14 2008-04-14 Pochodne galantaminy jako proleki do leczenia chorób mózgu u ludzi

Country Status (8)

Country Link
EP (1) EP2137192B8 (pl)
JP (1) JP5504253B2 (pl)
CN (1) CN102007129B (pl)
CA (1) CA2721007C (pl)
DK (1) DK2137192T3 (pl)
ES (1) ES2463715T3 (pl)
PL (1) PL2137192T3 (pl)
WO (1) WO2009127218A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3417862T (pt) * 2012-07-27 2021-08-06 Neurodyn Life Sciences Inc Biodisponibilidade cerebral da galantamina melhorada através de formulações selecionadas e administração transmucosal de pró-fármacos lipofílicos
EP3417862B1 (en) * 2012-07-27 2021-05-05 Neurodyn Life Sciences Inc. Enhanced brain bioavailability of galantamine by selected formulations and transmucosal administration of lipophilic prodrugs
CA2944019C (en) * 2014-03-25 2022-08-02 Synaptec Development Llc Treatment of autism
WO2015148480A1 (en) 2014-03-25 2015-10-01 Emicipi Llc Treatment of rett syndrome
US11219627B2 (en) * 2014-05-16 2022-01-11 Synaptec Development Llc Clearance of amyloid beta
EP4029867A1 (en) 2021-01-13 2022-07-20 Alpha Cognition Inc. Solid forms of galantamine benzoate gluconate
EP4186509A1 (en) 2021-11-26 2023-05-31 Alpha Cognition Inc. Alpha-1062 for treating traumatic brain injury
US12208167B1 (en) 2024-02-06 2025-01-28 Alpha Cognition Inc. Coated tablets for pH-dependent release of benzgalantamine

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150354A (en) 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
EP0363415B1 (en) 1987-05-04 2008-10-15 Davis, Bonnie Compounds for the treatment of alzheimer's disease
US6323196B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6323195B1 (en) 1993-10-15 2001-11-27 Aventis Pharmaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
US6316439B1 (en) 1993-10-15 2001-11-13 Aventis Pharamaceuticals Inc. Galanthamine derivatives as acetylcholinesterase inhibitors
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
WO1999021561A1 (en) * 1997-10-29 1999-05-06 Davis Bonnie M Method for treatment of disorders of attention
AU1430099A (en) 1998-12-01 2000-06-19 Sanochemia Pharmazeutika Aktiengesellschaft Use of galanthamine and galanthamine derivatives in the case of acute functionalbrain damage
CA2393301A1 (en) 1999-12-10 2001-06-21 Bonnie Davis Analogs of galanthamine and lycoramine as modulators of nicotinic receptors
CN1380883A (zh) 2000-03-31 2002-11-20 萨诺化学药物股份公司 雪花胺的新衍生物和类似物
US20030162770A1 (en) 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
CN1875004B (zh) 2003-09-26 2010-06-23 台湾神隆股份有限公司 那维啶酰胺衍生物的拆分
AT414125B (de) 2003-09-29 2006-09-15 Sanochemia Pharmazeutika Ag Neue derivate des 4a,5,9,10,11,12-hexahydro- benzofuro(3a,3,2)(2) benzazepin, verfahren zu deren herstellung sowie deren verwendung zur herstellung von arzneimitteln
EP1777222A1 (en) 2005-09-22 2007-04-25 Galantos Pharma GmbH Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment

Also Published As

Publication number Publication date
EP2137192B8 (en) 2014-06-11
EP2137192A1 (en) 2009-12-30
JP5504253B2 (ja) 2014-05-28
CN102007129B (zh) 2014-05-07
EP2137192B1 (en) 2014-02-19
CA2721007C (en) 2014-04-29
CA2721007A1 (en) 2009-10-22
CN102007129A (zh) 2011-04-06
JP2011516588A (ja) 2011-05-26
DK2137192T3 (da) 2014-05-26
WO2009127218A1 (en) 2009-10-22
ES2463715T3 (es) 2014-05-29

Similar Documents

Publication Publication Date Title
EP2262508A4 (en) SUBSTITUTED p-CHINONE DERIVATIVES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH OXIDATIVE STRESS
IL216399A0 (en) Pharmaceutical composition for the treatment of heart diseases
EP2187743A4 (en) FORMULATIONS FOR THE TREATMENT OF DISEASES OR EYE DISORDERS
IL209730A0 (en) Triazole derivatives useful for the treatment of diseases
EP2166837A4 (en) DRUG COMBINATION USEFUL FOR THE TREATMENT OF SKIN DISORDERS
IL200368A0 (en) Treatment of diseases characterized by inflammation
IL208357A0 (en) Spiro-indole derivatives for the treatment of parasitic diseases
PT2049127E (pt) Derivados n-metanocarba para tratamento de doenças cardíacas
GB2483419B (en) Formulations for the treatment of deep tissue pain
PL2137192T3 (pl) Pochodne galantaminy jako proleki do leczenia chorób mózgu u ludzi
IL211313A0 (en) Compounds, compositions and methods for the treatment of ??-amyloid diseases and synucleinopathies
ZA200905364B (en) Treatment of diseases characterized by inflammation
HUE037611T2 (hu) AMP-származékok szívbetegségek kezelésére
GB0906159D0 (en) Drug combination for the treatment of proteostatic diseases
PL2605769T3 (pl) Pochodne benzochinonu do leczenia chorób mitochondrialnych oczu
IL225755A0 (en) Amido-6 derivatives of epoxymorphinans-a5, 4 for the treatment of pain
PL392436A1 (pl) Pochodne arylosulfonamidów do leczenia chorób odśrodkowego układu nerwowego
IL213606A0 (en) 1-amino-alkylcyclohexane derivatives for the treatment of inflamatory skin diseases
IL220134A0 (en) Thiazole derivatives for the treatment of diseases such as cancer
IL209036A0 (en) Device for stimulating areas of the human brain
GB0814043D0 (en) The treatment of skin disorders
IL207753A0 (en) Substituted 4-aminocyclohexane derivatives for the treatment of pain
GB0801511D0 (en) The treatment of ophthalmic diseases
GB0716834D0 (en) New formulation for treatment of skin disorders
GB0901727D0 (en) The treatment of ophthalmic diseases